CD274 and hepatocellular carcinoma: In 2020, FDA approved atezolizumab (anti-PDL1) combined with bevacizumab (VEGF inhibitor) for the treatment of patients with unresectable or metastatic HCC based on IMbrave150 trial data, showing better overall survival (OS) and progression-free survival (PFS) compared with sorafenib, and this regimen became a new first-line treatment for advanced HCC [17].